Press Release
Back arrow blue Back

Flatiron Health Announces Strategic Relationships with Celgene and Amgen to Further Advance Personalized Medicine for Cancer Patients and Accelerate Clinical Research

Celgene Switzerland LLC and Amgen Ventures also join other strategic investors as part of Flatiron Health’s Series C fundraising round to bolster Flatiron’s leading cloud-based oncology platform.

NEW YORK, NY, April 8, 2016Flatiron Health today announced an expansion of its relationships with Celgene Corporation and Amgen Inc. Through individual agreements, Celgene and Amgen will collaborate with Flatiron Health with the goals of accelerating clinical research, advancing personalized medicine and enhancing treatment options for cancer patients. In addition, Celgene Switzerland LLC and Amgen Ventures have invested in Flatiron Health’s recently announced fundraising round.

“With only four percent of adult cancer patients enrolled in a clinical trial, there is a pressing need to better understand how new and existing therapies work in ‘the real world’ so that we can further enhance patient care,” said Amy Abernethy, MD, PhD, Chief Medical Officer and Senior Vice President, Oncology at Flatiron Health. “At Flatiron Health, we are unlocking key clinical and research results from disparate sources, in near real-time, to help answer the questions that cancer care providers, researchers and life science companies prioritize. Through our offerings, we can support companies such as Celgene and Amgen in better understanding today’s medical needs while enabling research advances and faster delivery of therapies to patients.”

To help researchers and life science companies answer a broad range of exploratory commercial, medical and research questions, Flatiron Health combines industry-first technology, proprietary data processing capabilities and an extensive understanding of oncology to deliver a continuously aggregating data resource. This enables life science companies to develop deep, real-world insights into the constantly evolving oncology landscape, support healthcare decision-making and enhance patient outcomes.

Celgene expands use of Flatiron Health’s OncologyCloud™ software platform
In addition to its equity investment, Celgene will continue to strengthen its relationship with Flatiron Health to support Celgene’s strategic objective of leveraging real-world evidence to identify novel approaches to patient therapy and accelerate Celgene’s bold pursuits to improve patients’ lives. Celgene will work with Flatiron to further shape its innovative offering, which uses longitudinal real-world data at scale as a more efficient and timely alternative to traditional prospective registries. Separately, Flatiron Health and Celgene will continue providing patient access tools at the point of care within Flatiron Health’s OncologyCloudTM software platform.

“Celgene is committed to pursuing innovative therapies and treatment diagnostics that can improve patients’ lives. The work we’re doing with Flatiron is an ideal opportunity to complement our scientific and clinical trial expertise with targeted insights from comprehensive real-world data,” said Alan Colowick, executive vice president at Celgene. “Through our investment and relationship, Celgene expects to gain critical information from Flatiron’s unique platform that will be useful in our quest to discover and develop important therapies for patients.”

Powering Amgen’s OSCER Database
Flatiron Health will continue supporting Amgen’s customized resource of real-world oncology data: Oncology Services Comprehensive Electronic Records (OSCER). First launched in 2004 and powered by Flatiron Health since January 2015, OSCER allows researchers to conduct observational studies and publish insights on cancer care. OSCER powered by Flatiron Health will further enable Amgen’s oncology teams to optimize data for scientific research, deliver increased value to physicians and patients, and enhance commercialization efforts.

In addition, Amgen will leverage Flatiron Health’s products that integrate de-identified clinical treatment and outcomes data with genomic profiling data to accelerate clinical research efforts and inform the development of novel targeted therapies.

“For more than a decade, Amgen has captured and analyzed important oncology treatment data from electronic medical records. We have experienced first-hand the tremendous value of informing clinical research with real world data,” said Elliott Levy, senior vice president, Global Development at Amgen. “Our collaboration with Flatiron Health will help us take observational research to the next level. Ultimately, we utilize these high-quality oncology data to inform clinical trial design and enhance our understanding of real-world utilization patterns.”

###